Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Identifieur interne : 002871 ( PubMed/Checkpoint ); précédent : 002870; suivant : 002872Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Auteurs : E. Munzone [Italie] ; A. Giobbie-Hurder [États-Unis] ; B A Gusterson ; E. Mallon [Royaume-Uni] ; G. Viale [Italie] ; B. Thürlimann [Suisse] ; B. Ejlertsen [Danemark] ; G. Macgrogan ; F. Bibeau [France] ; G. Lelkaitis [Danemark] ; K N Price ; R D Gelber [États-Unis] ; A S Coates [Australie] ; A. Goldhirsch [Italie] ; M. Colleoni [Italie]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques hormonaux (administration et posologie), Carcinome canalaire du sein (diagnostic), Carcinome canalaire du sein (traitement médicamenteux), Femelle, Humains, Nitriles (administration et posologie), Récidive tumorale locale (diagnostic), Récidive tumorale locale (traitement médicamenteux), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tamoxifène (administration et posologie), Traitement médicamenteux adjuvant, Triazoles (administration et posologie), Tumeurs du sein (diagnostic), Tumeurs du sein (traitement médicamenteux), Études de cohortes, Études de suivi.
- MESH :
- administration et posologie : Antinéoplasiques hormonaux, Nitriles, Tamoxifène, Triazoles.
- diagnostic : Carcinome canalaire du sein, Récidive tumorale locale, Tumeurs du sein.
- traitement médicamenteux : Carcinome canalaire du sein, Récidive tumorale locale, Tumeurs du sein.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Traitement médicamenteux adjuvant, Études de cohortes, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal (administration & dosage), Breast Neoplasms (diagnosis), Breast Neoplasms (drug therapy), Carcinoma, Ductal, Breast (diagnosis), Carcinoma, Ductal, Breast (drug therapy), Chemotherapy, Adjuvant, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Recurrence, Local (diagnosis), Neoplasm Recurrence, Local (drug therapy), Nitriles (administration & dosage), Tamoxifen (administration & dosage), Treatment Outcome, Triazoles (administration & dosage).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Hormonal, Nitriles, Tamoxifen, Triazoles.
- diagnosis : Breast Neoplasms, Carcinoma, Ductal, Breast, Neoplasm Recurrence, Local.
- drug therapy : Breast Neoplasms, Carcinoma, Ductal, Breast, Neoplasm Recurrence, Local.
- Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Treatment Outcome.
Abstract
We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.
DOI: 10.1093/annonc/mdv391
PubMed: 26387144
Affiliations:
- Australie, Danemark, France, Italie, Royaume-Uni, Suisse, États-Unis
- Canton de Berne, Hovedstaden, Languedoc-Roussillon, Lombardie, Massachusetts, Nouvelle-Galles du Sud, Occitanie (région administrative)
- Berne, Boston, Copenhague, Milan, Montpellier, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26387144Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E" last="Munzone">E. Munzone</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy elisabetta.munzone@ieo.it.</nlm:affiliation><country wicri:rule="url">Italie</country><wicri:regionArea>Division of Medical Senology, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A" last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B A" last="Gusterson">B A Gusterson</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, Glasgow University, Glasgow.</nlm:affiliation><wicri:noCountry code="subField">Glasgow</wicri:noCountry></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E" last="Mallon">E. Mallon</name><affiliation wicri:level="1"><nlm:affiliation>Southern General Hospital, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Southern General Hospital, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G" last="Viale">G. Viale</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B" last="Thürlimann">B. Thürlimann</name><affiliation wicri:level="3"><nlm:affiliation>Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B" last="Ejlertsen">B. Ejlertsen</name><affiliation wicri:level="3"><nlm:affiliation>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G" last="Macgrogan">G. Macgrogan</name><affiliation><nlm:affiliation>Department of Pathology, Institut Bergonié, Bordeaux.</nlm:affiliation><wicri:noCountry code="subField">Bordeaux</wicri:noCountry></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F" last="Bibeau">F. Bibeau</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G" last="Lelkaitis">G. Lelkaitis</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Pathology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K N" last="Price">K N Price</name><affiliation><nlm:affiliation>International Breast Cancer Study Group (IBCSG) Statistical Center.</nlm:affiliation><wicri:noCountry code="no comma">International Breast Cancer Study Group (IBCSG) Statistical Center.</wicri:noCountry></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R D" last="Gelber">R D Gelber</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A S" last="Coates">A S Coates</name><affiliation wicri:level="4"><nlm:affiliation>International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A" last="Goldhirsch">A. Goldhirsch</name><affiliation wicri:level="3"><nlm:affiliation>Program of Breast Health, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Program of Breast Health, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M" last="Colleoni">M. Colleoni</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Senology, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26387144</idno><idno type="pmid">26387144</idno><idno type="doi">10.1093/annonc/mdv391</idno><idno type="wicri:Area/PubMed/Corpus">002620</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002620</idno><idno type="wicri:Area/PubMed/Curation">002551</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002551</idno><idno type="wicri:Area/PubMed/Checkpoint">002551</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002551</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E" last="Munzone">E. Munzone</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy elisabetta.munzone@ieo.it.</nlm:affiliation><country wicri:rule="url">Italie</country><wicri:regionArea>Division of Medical Senology, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A" last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B A" last="Gusterson">B A Gusterson</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, Glasgow University, Glasgow.</nlm:affiliation><wicri:noCountry code="subField">Glasgow</wicri:noCountry></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E" last="Mallon">E. Mallon</name><affiliation wicri:level="1"><nlm:affiliation>Southern General Hospital, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Southern General Hospital, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G" last="Viale">G. Viale</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B" last="Thürlimann">B. Thürlimann</name><affiliation wicri:level="3"><nlm:affiliation>Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B" last="Ejlertsen">B. Ejlertsen</name><affiliation wicri:level="3"><nlm:affiliation>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G" last="Macgrogan">G. Macgrogan</name><affiliation><nlm:affiliation>Department of Pathology, Institut Bergonié, Bordeaux.</nlm:affiliation><wicri:noCountry code="subField">Bordeaux</wicri:noCountry></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F" last="Bibeau">F. Bibeau</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G" last="Lelkaitis">G. Lelkaitis</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Pathology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K N" last="Price">K N Price</name><affiliation><nlm:affiliation>International Breast Cancer Study Group (IBCSG) Statistical Center.</nlm:affiliation><wicri:noCountry code="no comma">International Breast Cancer Study Group (IBCSG) Statistical Center.</wicri:noCountry></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R D" last="Gelber">R D Gelber</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A S" last="Coates">A S Coates</name><affiliation wicri:level="4"><nlm:affiliation>International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A" last="Goldhirsch">A. Goldhirsch</name><affiliation wicri:level="3"><nlm:affiliation>Program of Breast Health, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Program of Breast Health, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M" last="Colleoni">M. Colleoni</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Senology, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents, Hormonal (administration & dosage)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (drug therapy)</term><term>Carcinoma, Ductal, Breast (diagnosis)</term><term>Carcinoma, Ductal, Breast (drug therapy)</term><term>Chemotherapy, Adjuvant</term><term>Cohort Studies</term><term>Disease-Free Survival</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (diagnosis)</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Nitriles (administration & dosage)</term><term>Tamoxifen (administration & dosage)</term><term>Treatment Outcome</term><term>Triazoles (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques hormonaux (administration et posologie)</term><term>Carcinome canalaire du sein (diagnostic)</term><term>Carcinome canalaire du sein (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Nitriles (administration et posologie)</term><term>Récidive tumorale locale (diagnostic)</term><term>Récidive tumorale locale (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tamoxifène (administration et posologie)</term><term>Traitement médicamenteux adjuvant</term><term>Triazoles (administration et posologie)</term><term>Tumeurs du sein (diagnostic)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de cohortes</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Hormonal</term><term>Nitriles</term><term>Tamoxifen</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques hormonaux</term><term>Nitriles</term><term>Tamoxifène</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Récidive tumorale locale</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Récidive tumorale locale</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chemotherapy, Adjuvant</term><term>Cohort Studies</term><term>Disease-Free Survival</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term><term>Études de cohortes</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26387144</PMID><DateCreated><Year>2015</Year><Month>11</Month><Day>26</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.</ArticleTitle><Pagination><MedlinePgn>2442-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdv391</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.</AbstractText><AbstractText Label="CLINICALTRIALSGOV" NlmCategory="UNASSIGNED">NCT00004205.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munzone</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy elisabetta.munzone@ieo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giobbie-Hurder</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gusterson</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Institute of Cancer Sciences, Glasgow University, Glasgow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Southern General Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thürlimann</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ejlertsen</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacGrogan</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institut Bergonié, Bordeaux.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibeau</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lelkaitis</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>K N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>International Breast Cancer Study Group (IBCSG) Statistical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelber</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldhirsch</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program of Breast Health, European Institute of Oncology, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colleoni</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Senology, European Institute of Oncology, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Breast Cancer Study Group and the BIG 1-98 Collaborative Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00004205</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LKK855W8I</RegistryNumber><NameOfSubstance UI="C067431">letrozole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Histopathology. 1983 Jul;7(4):525-36</RefSource><PMID Version="1">6884999</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Sep;24(9):2206-23</RefSource><PMID Version="1">23917950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Clin North Am. 1990 Aug;70(4):963-75</RefSource><PMID Version="1">2164716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 May;17(5):1442-8</RefSource><PMID Version="1">10334529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Feb 10;25(5):486-92</RefSource><PMID Version="1">17200148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg Pathol. 2008 Apr;32(4):513-23</RefSource><PMID Version="1">18223478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2008 Oct;216(2):141-50</RefSource><PMID Version="1">18720457</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Dec 1;26(34):5569-75</RefSource><PMID Version="1">18981464</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2009 May;197(5):674-7</RefSource><PMID Version="1">18789411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 May 20;101(10):736-50</RefSource><PMID Version="1">19436038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Trials. 2009 Jun;6(3):272-87</RefSource><PMID Version="1">19528136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2009 Aug;20(8):1319-29</RefSource><PMID Version="1">19535820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2009 Dec;6(12):718-30</RefSource><PMID Version="1">19942925</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 1;28(1):99-104</RefSource><PMID Version="1">19917872</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Oncol. 2010 Jun;4(3):192-208</RefSource><PMID Version="1">20452298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2010 Sep;222(1):64-75</RefSource><PMID Version="1">20593406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource><PMID Version="1">21709140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Oct;22(10):2201-7</RefSource><PMID Version="1">21335417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast. 2011 Oct;20 Suppl 3:S153-7</RefSource><PMID Version="1">22015285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 Nov;12(12):1101-8</RefSource><PMID Version="1">22018631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Jun;23(6):1428-36</RefSource><PMID Version="1">22039080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2013 Apr;139(4):617-23</RefSource><PMID Version="1">23269487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1978 Nov;42(5):2334-42</RefSource><PMID Version="1">214219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ANZ J Surg. 2001 Jan;71(1):27-31</RefSource><PMID Version="1">11167594</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Pathol. 1986 Jan;17(1):34-8</RefSource><PMID Version="1">3002950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4658543 [Available on 12/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">cribriform</Keyword><Keyword MajorTopicYN="N">letrozole</Keyword><Keyword MajorTopicYN="N">mucinous</Keyword><Keyword MajorTopicYN="N">tamoxifen</Keyword><Keyword MajorTopicYN="N">tubular</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26387144</ArticleId><ArticleId IdType="pii">mdv391</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdv391</ArticleId><ArticleId IdType="pmc">PMC4658543</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Danemark</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Canton de Berne</li><li>Hovedstaden</li><li>Languedoc-Roussillon</li><li>Lombardie</li><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Occitanie (région administrative)</li></region><settlement><li>Berne</li><li>Boston</li><li>Copenhague</li><li>Milan</li><li>Montpellier</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><noCountry><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B A" last="Gusterson">B A Gusterson</name><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G" last="Macgrogan">G. Macgrogan</name><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K N" last="Price">K N Price</name></noCountry><country name="Italie"><region name="Lombardie"><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E" last="Munzone">E. Munzone</name></region><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M" last="Colleoni">M. Colleoni</name><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A" last="Goldhirsch">A. Goldhirsch</name><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G" last="Viale">G. Viale</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A" last="Giobbie-Hurder">A. Giobbie-Hurder</name></region><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R D" last="Gelber">R D Gelber</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E" last="Mallon">E. Mallon</name></noRegion></country><country name="Suisse"><region name="Canton de Berne"><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B" last="Thürlimann">B. Thürlimann</name></region></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B" last="Ejlertsen">B. Ejlertsen</name></region><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G" last="Lelkaitis">G. Lelkaitis</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F" last="Bibeau">F. Bibeau</name></region></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A S" last="Coates">A S Coates</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002871 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002871 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26387144
|texte= Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26387144" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |